Our results show that increased FRMD6 expression reduces the baseline activity of Erk1/2 and AKT and diminishes the FBS-induced activation of Erk1/2 and AKT kinases in GBM cells (Figure 7C–7D), further supporting the inhibitory effect of FRMD6 on activity of c-Met/PDGFR RTKs. The gene discussed is MET; the disease is glioblastoma.